Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxyhydrogen Nanobubble Infusion in Parkinsonism
NCT07466381Phase 3Completed
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial in Parkinson's disease (PD). Primary endpoints: Parkinsonism severity level at 2 months, Cognitive function at 2 months and 1 more. Started Nov 2024; status: completed.
02
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07466381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07466381.